AKTS

Aktis Oncology Inc

Feb 25 • 02:14PM ET

19.30

-0.70 -3.50 %

Healthcare • Biotechnology • USA • NASD

Feb 24, 8:07 AMFDA grants Fast Track designation to Aktis Oncology’s Nectin-4–targeting radioconjugate AKY-1189 for advanced urothelial cancer

Held by: VTI VXF VTWO TMED BMED VTWG VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	47.48%	Shs Outstand	52.52M	Perf Week	9.47%
Market Cap	1.01B	Forward P/E	-	EPS next Y	-	Insider Trans	34.17%	Shs Float	27.59M	Perf Month	-10.73%
Enterprise Value	1.06B	PEG	-	EPS next Q	-21.59	Inst Own	9.19%	Short Float	0.71%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	5.54%	Short Ratio	0.52	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.20M	Perf YTD	-13.84%
Book/sh	-1.67	P/C	3.41	EPS next 5Y	-	ROE	-	52W High	29.16 -33.81%	Perf Year	-
Cash/sh	5.66	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	16.80 14.88%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.82% 8.02%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.73	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.98	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.46	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	15.98	EPS Q/Q	-	SMA20	0.55%	Beta	-	Target Price	31.67
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	-2.98%	Rel Volume	0.41	Prev Close	20.00
Employees	-	LT Debt/Eq	0.04	Earnings	Dec 03	SMA200	-2.98%	Avg Volume	379.02K	Price	19.30
IPO	Jan 09, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	116,630	Change	-3.50%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-03-26	Initiated	TD Cowen	Buy
Feb-03-26	Initiated	Leerink Partners	Outperform	$31
Feb-03-26	Initiated	JP Morgan	Overweight	$30
Feb-03-26	Initiated	BofA Securities	Buy	$34

Feb-24-26 04:05PM	Aktis Oncology to Present at Upcoming March Investor Conferences (GlobeNewswire)
12:02PM	Medtronic Diabetes Unit MiniMed Seeks $784 Million in US IPO (Bloomberg)
08:00AM	Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate (GlobeNewswire)
Feb-05-26 01:21PM	Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut (Reuters)
Feb-03-26 09:34AM	Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls (The Fly)
11:39AM	Loading…
Jan-27-26 11:39AM	Should You Buy PICS Stock After the PicPay IPO? (Barchart)
Jan-19-26 08:45AM	Huge Insider Buying Now at This Insurance Giant and 2 Biotechs (24/7 Wall St.)
Jan-17-26 07:00AM	MarketBeat Week in Review 01/12 - 01/16 (MarketBeat)
Jan-14-26 09:31AM	A Fresh IPO That Long-Term Investors Shouldn't Ignore (MarketBeat)
Jan-13-26 06:30AM	Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-09-26 12:58PM	Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets (Business Wire)

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foley Todd	Director	Jan 12 '26	Buy	18.00	232,870	4,191,660	4,235,403	Jan 14 06:20 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Jan 12 '26	Buy	18.00	1,112,777	20,029,986	10,260,064	Jan 14 06:19 PM
GADICKE ANSBERT	10% Owner	Jan 12 '26	Buy	18.00	1,112,777	20,029,986	10,260,064	Jan 14 06:17 PM
EcoR1 Capital, LLC	Director	Jan 12 '26	Buy	18.00	2,222,222	39,999,996	4,348,658	Jan 12 08:28 PM
Vida Ventures II, LLC	10% Owner	Jan 12 '26	Buy	18.00	835,000	15,030,000	5,671,825	Jan 12 05:10 PM
Kim Helen Susan	Director	Jan 12 '26	Buy	18.00	835,000	15,030,000	5,671,825	Jan 12 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKTS

Aktis Oncology Inc

Upgrade your FINVIZ experience